Selank

Selank (TP-7) is a synthetic heptapeptide developed at the Institute of Molecular Genetics of the Russian Academy of Sciences. It is a structural analog of the naturally occurring immunomodulatory peptide tuftsin, with additional amino acids attached to enhance stability and central nervous system activity. Selank has been approved in Russia since 2009 as a nasal spray for the treatment of generalized anxiety disorder and as a nootropic — making it one of the few peptides with actual regulatory approval for a cognitive or psychiatric indication, even if that approval comes from a regulatory system that Western researchers often view with appropriate skepticism.

The compound occupies an interesting position in the peptide landscape: it has legitimate human clinical trial data from Russian institutions, documented anxiolytic and cognitive effects, an established safety record from clinical use in Russia, and a plausible multi-pathway mechanism of action. It also has virtually no Western clinical trial data, limited independent replication of Russian findings by international research groups, and no FDA approval or recognition. This creates a familiar tension in research peptide evaluation — promising data from systems that don't fully meet Western evidence standards.

This guide covers what Selank is, how it works, what the available human data shows, where the evidence gaps lie, and the honest assessment of its position in the nootropic and anxiolytic peptide space.

What Is Selank?

Selank's full sequence is Thr-Lys-Pro-Arg-Pro-Gly-Pro — a heptapeptide that incorporates the tetrapeptide tuftsin (Thr-Lys-Pro-Arg) as its core structure, with a C-terminal Pro-Gly-Pro extension designed to increase metabolic stability and half-life. Tuftsin is a naturally occurring immunostimulatory peptide derived from the Fc region of immunoglobulin G (IgG), and it plays a role in phagocytosis, immune cell activation, and natural killer cell activity.

The addition of the Pro-Gly-Pro sequence transforms tuftsin from a purely immunomodulatory peptide into a compound with significant central nervous system activity, including anxiolytic, nootropic, and antidepressant effects. This structure-activity relationship is well-characterized in the Russian literature, though the specific mechanisms by which the C-terminal extension confers CNS activity are not fully elucidated.

Selank is administered as an intranasal spray in its approved Russian formulation, which is a 0.15% solution. The intranasal route is preferred because it provides direct access to the CNS via the olfactory and trigeminal nerve pathways, similar to the approach used with intranasal oxytocin.

How Selank Works: Mechanism of Action

GABA System Modulation

Selank's anxiolytic effects appear to be mediated significantly through modulation of the GABAergic system. Research has shown that Selank influences the expression of genes encoding GABA-A receptor subunits, potentially altering receptor composition and sensitivity. Specifically, Selank appears to enhance GABAergic inhibitory neurotransmission without the sedation, tolerance, or dependence associated with benzodiazepines — which also act through the GABA-A receptor but via a different mechanism.

The distinction from benzodiazepines is critical. Benzodiazepines act as positive allosteric modulators that directly potentiate GABA-A receptor function, producing rapid anxiolysis but also sedation, cognitive impairment, tolerance, and physical dependence. Selank appears to modulate GABAergic tone through gene expression changes that shift receptor subunit composition — a slower, more subtle mechanism that may explain the anxiolytic effect without the typical benzodiazepine side effect profile.

Serotonin Metabolism

Selank has been shown to influence serotonin metabolism, affecting the expression of enzymes involved in serotonin synthesis and degradation. Research indicates it may modulate tryptophan hydroxylase (the rate-limiting enzyme in serotonin synthesis) and monoamine oxidase (MAO, which degrades serotonin). The net effect appears to be stabilization of serotonergic tone rather than simple increase or decrease.

Brain-Derived Neurotrophic Factor (BDNF)

Selank has been reported to increase the expression of brain-derived neurotrophic factor (BDNF) in the hippocampus. BDNF is critical for synaptic plasticity, learning, memory formation, and neuronal survival. Many established antidepressants (SSRIs, SNRIs) also increase BDNF expression, and the "neurotrophin hypothesis of depression" suggests that BDNF upregulation is a key mediator of antidepressant effects.

The BDNF-enhancing property provides a plausible mechanism for Selank's reported cognitive-enhancing and antidepressant effects and connects it to well-established neurobiology of mood and cognition.

Enkephalin Modulation

Selank influences the expression and metabolism of enkephalins — endogenous opioid peptides involved in pain modulation, stress response, and emotional regulation. Specifically, Selank appears to inhibit enkephalin-degrading enzymes, increasing the availability of endogenous enkephalins. This mechanism could contribute to both anxiolytic effects (through opioid-mediated stress dampening) and analgesic effects.

Immunomodulatory Effects

Retaining the immunomodulatory properties of its parent compound tuftsin, Selank has documented effects on immune function, including modulation of cytokine expression (IL-6, IL-10, TNF-alpha), enhancement of natural killer cell activity, and regulation of inflammatory pathways. These immune effects are potentially relevant for individuals with anxiety or depression driven by chronic inflammation — a connection that has gained increasing recognition in psychiatry.

Human Clinical Data

Russian Approval Studies

Selank received Russian regulatory approval in 2009 based on clinical trial data demonstrating anxiolytic efficacy comparable to medazepam (a benzodiazepine) in patients with generalized anxiety disorder, with a significantly better side effect profile:

• No sedation or cognitive impairment
• No tolerance development with repeated use
• No withdrawal symptoms upon discontinuation
• No abuse or dependence potential

Cognitive Enhancement Studies

Human studies in Russia have reported cognitive-enhancing effects of Selank, including improvements in attention, memory consolidation, and information processing under stress conditions. These effects have been assessed using neuropsychological testing batteries and EEG (electroencephalography) measurements showing changes in brain wave patterns consistent with enhanced cognitive processing.

Limitations of the Evidence

The critical limitation is that virtually all human clinical data comes from Russian research institutions, with limited independent replication by Western groups. The Russian regulatory system has different standards for clinical trial design, statistical analysis, and reporting than the FDA or EMA. This doesn't mean the data is wrong, but it does mean it hasn't been subjected to the same level of external scrutiny that Western regulatory submissions require.

Additionally, publication bias is a concern — positive results are more likely to be published, and the full clinical trial dataset may not be publicly available.

Selank vs. Semax

Selank is frequently compared to Semax, another Russian-developed peptide nootropic. The key differences:

• Selank: Tuftsin-based, primarily anxiolytic with secondary nootropic effects, GABA/serotonin/BDNF mechanism
• Semax: ACTH-based, primarily nootropic with secondary mood effects, BDNF/NGF/dopamine mechanism

Some users combine both peptides (the "Selank + Semax stack"), though there is limited formal research on the combination. The two compounds target partially overlapping but distinct neurochemical pathways, which provides a theoretical rationale for combination use.

For details on Semax, see our complete Semax profile. For other nootropic peptides, see our profiles on Dihexa, Noopept, and Cerebrolysin.

Side Effects and Safety

Reported Side Effects

Selank's safety profile, based on Russian clinical data and post-marketing surveillance, is remarkably benign:

• Nasal irritation: Mild and transient with intranasal administration
• Fatigue: Occasionally reported, typically mild
• Allergic reactions: Rare; more common in individuals with known peptide sensitivities

No serious adverse events have been attributed to Selank in the published literature or post-marketing data. There are no reports of tolerance, dependence, withdrawal, or abuse — a significant differentiator from benzodiazepines and other GABAergic anxiolytics.

What We Don't Know

• Long-term safety beyond the Russian post-marketing surveillance period
• Interactions with Western psychiatric medications (SSRIs, SNRIs, benzodiazepines)
• Safety in pregnancy and lactation
• Safety in pediatric populations
• Effects in individuals with compromised immune function (given the immunomodulatory properties)

Dosing and Administration

Russian Approved Protocol

The approved Russian dosing regimen is Selank 0.15% nasal spray, 2-3 drops per nostril, 3 times daily, for a treatment course of 14 days. Courses can be repeated after a break, though the optimal inter-course interval is not well-defined.

Research Community Protocols

In the Western research peptide community, various dosing approaches are used:

• Intranasal: 200-400 mcg per dose, 1-3 times daily
• Subcutaneous injection: 250-500 mcg per dose, 1-2 times daily
• Course duration: Typically 2-4 weeks, with 2-4 week breaks between courses

These are not clinically validated protocols and are based on community experience rather than controlled dose-finding studies.

Legal Status and Availability

• Russia: Approved and commercially available as a nasal spray
• United States: Not FDA-approved; available as a research chemical
• European Union: Not approved; available through research suppliers
• WADA: Not currently listed as a prohibited substance

The Bottom Line

Selank is a genuinely interesting compound with a plausible multi-pathway mechanism of action, documented regulatory approval in Russia, and a safety profile that appears favorable compared to existing anxiolytic medications. The anxiolytic and nootropic effects are supported by human data, though that data comes predominantly from Russian institutions with limited Western replication.

For individuals seeking an anxiolytic peptide with nootropic properties and minimal sedation or dependence risk, Selank represents one of the more scientifically grounded options in the research peptide space. However, the absence of FDA-approved clinical data means that anyone using Selank outside of Russia is navigating the same uncertainty that applies to most research peptides — accepting data from a regulatory system with different standards and quality-controlled products of variable reliability.

For related nootropic peptides, see our profiles on Semax, Dihexa, Noopept, and Cerebrolysin. For peptide safety guidance, see our peptide safety guide.

Frequently Asked Questions